Press releases
Access archived Guidant press releases
Access archived BTG press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Dec 8, 2011World's first and only 16-contact percutaneous lead provides innovative, new option for physicians to treat chronic pain
Boston Scientific Corporation (NYSE: BSX) announces U.S. Food and Drug Administration (FDA) approval of the Infinion™ 16 Percutaneous...
-
Nov 30, 2011Extended ICD/CRT-D program offers warranties up to 10 years
Boston Scientific Corporation (NYSE: BSX) announced that, along with today's introduction of a new family of INCEPTA™ and ENERGEN™ implantable...
-
Nov 30, 2011New family of cardiac devices offers excellent longevity and industry's longest warranty
Boston Scientific Corporation (NYSE: BSX) announces FDA approval of its INCEPTA™, ENERGEN™ and PUNCTUA™ cardiac resynchronization therapy...
-
Nov 22, 2011Approval marks transition to internally manufactured everolimus-eluting stent in the U.S.
Boston Scientific Corporation (NYSE: BSX) announces U.S. Food and Drug Administration (FDA) approval for the PROMUS Element™ Plus Everolimus-Eluting...
-
Nov 18, 2011
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Piper Jaffray 23rd Annual Healthcare Conference on November 30 in New...
-
Nov 16, 2011Innovative left atrial appendage closure device offers proven alternative to anticoagulant drugs for patients in atrial fibrillation at high risk for stroke
Boston Scientific Corporation's (NYSE: BSX) WATCHMAN® Left Atrial Appendage (LAA) Closure Device has been implanted in the first patients in Latin...
-
Nov 15, 2011
Boston Scientific Corporation (NYSE: BSX) commends the leadership of Senator Al Franken (D-MN), Senator Lamar Alexander (R-TN) and Senator John Kerry...
-
Nov 11, 2011Positive results from COBRA trial presented at TCT
Boston Scientific Corporation (NYSE: BSX) welcomed positive outcomes from the COBRA clinical trial, which evaluated post-dilation of...
-
Nov 11, 2011EVOLVE trial evaluates fourth-generation everolimus-eluting coronary stent with ultra-thin abluminal bioabsorbable polymer
Boston Scientific Corporation (NYSE: BSX) reports results from the EVOLVE First Human Use trial demonstrating the non-inferiority of...
-
Nov 8, 2011
Boston Scientific Corporation (NYSE: BSX) reports positive outcomes from the CABANA post-approval study of the Carotid WALLSTENT®...
-
Nov 8, 2011PLATINUM Long Lesion clinical results presented at TCT show no cardiac death, heart attack or stent thrombosis at one year
Boston Scientific Corporation (NYSE: BSX) reports clinical endpoint data from its PLATINUM Long Lesion trial, demonstrating excellent...
-
Nov 8, 2011Long-term results presented from two studies evaluating advanced paclitaxel-eluting stent
Boston Scientific Corporation (NYSE: BSX) reports positive long-term data from the PERSEUS clinical program, which demonstrated...
-
Nov 2, 2011Multi-center study published in Gastrointestinal Endoscopy is largest ever reported on peroral cholangioscopy
Boston Scientific Corporation (NYSE: BSX) welcomes study results published in the October issue of Gastrointestinal Endoscopy showing an overall...
-
Nov 1, 2011Clinical presentations to include 12-month data on fourth-generation SYNERGY™ Stent
Boston Scientific Corporation (NYSE: BSX) releases the schedule of its major events and product-related clinical research for the Cardiovascular...
-
Oct 27, 2011Video demonstration of CardioTeach™ app by Dr. Kenneth Stein available online
Boston Scientific Corporation (NYSE: BSX) introduces its CardioTeach™ iPad® app, an industry-first, free educational resource to help healthcare...
-
Oct 20, 2011
Boston Scientific Corporation (NYSE: BSX) announces financial results for the third quarter ended September 30, 2011, as well as updated sales and...
-
Oct 18, 2011
Boston Scientific Corporation (NYSE: BSX) has completed enrollment in a clinical trial to evaluate its WallFlex® Biliary RX Fully Covered Stent for...
-
Oct 17, 2011Company's everolimus-eluting platinum chromium stent now being marketed in world's second-largest DES market
Boston Scientific Corporation (NYSE: BSX) has begun a phased launch of its PROMUS Element™ Everolimus-Eluting Platinum Chromium Coronary Stent System...
-
Oct 14, 2011
Boston Scientific Corporation (NYSE: BSX) welcomes yesterday's introduction of the Medical Device Regulatory Improvement Act, sponsored by Sen. Amy...
-
Oct 11, 2011
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the third quarter ended September 30, 2011...
-
Oct 5, 2011Third-generation bare-metal stent designed to offer improved acute performance in treating patients with coronary artery disease
Boston Scientific Corporation (NYSE: BSX) has started patient enrollment in the OMEGA clinical trial, designed to evaluate the safety and effectiveness...
-
Sep 29, 2011Study designed to assess preliminary safety and efficacy of chronic vagal nerve stimulation in heart failure patients
Boston Scientific Corporation (NYSE: BSX) has enrolled the first patients in its NECTAR-HF (NEural Cardiac TherApy foR Heart Failure) clinical trial....
-
Sep 28, 2011
Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Court of Appeals for the Federal Circuit found in favor of the Company in a...
-
Sep 19, 2011Ultra-low profile, highly deliverable balloon dilatation catheter offers physicians exceptional performance in peripheral angioplasty procedures
Boston Scientific Corporation (NYSE: BSX) has launched its Coyote™ Balloon Catheter, a highly deliverable and ultra-low profile 0.014 inch balloon...
-
Sep 15, 2011Company supports women's health through online community launched by American Urogynecologic Society (AUGS) at annual meeting
Boston Scientific Corporation (NYSE: BSX) is further supporting the advancement of women's health as the founding sponsor of the American...
-
Sep 13, 2011Mahoney Has Served as Worldwide Chairman, Medical Device and Diagnostics Group, Johnson & Johnson
Attracting one of med-tech's most inspiring leaders, Boston Scientific Corporation (NYSE: BSX) has named Michael Mahoney, 46, as President of the...
-
Sep 9, 2011
Boston Scientific Corporation (NYSE: BSX) today issued the following statement from John Pedersen, Senior Vice President and President of the Company's...
-
Sep 2, 2011
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Morgan Stanley Global Healthcare Conference on September 14 in New York....
-
Sep 2, 2011
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Morgan Stanley Global Healthcare Conference on September 14 in New York....
-
Aug 10, 2011Company also introduces industry's first iPhone®/iPad® app for healthcare professionals using SCS
Boston Scientific Corporation (NYSE: BSX) has launched its Neuromodulation Learning Institute™ (NLI), a clinical education program and online...
-
Aug 9, 2011Company's fully covered metal stent now approved in Canada for use in treating benign biliary strictures
Natick, MA (August 9, 2011) – Boston Scientific Corporation’s (NYSE: BSX) WallFlex® Biliary RX Fully Covered Stent has received Health Canada approval for the treatment of benign biliary...
-
Aug 8, 2011
Boston Scientific Corporation (NYSE: BSX) today announces the U.S. Court of Appeals for the First Circuit has affirmed the dismissal of a...
-
Aug 8, 2011Investment supported by grant funding from Government through IDA Ireland
Clonmel, 8th August 2011 – Boston Scientific Corporation (NYSE: BSX) and Irish Minister for Jobs, Enterprise and Innovation, Richard Bruton TD, announced that the Company is investing €26...
-
Jul 28, 2011Company also announces new share repurchase, China investment and restructuring program
Boston Scientific Corporation (NYSE: BSX) today announces financial results for the second quarter ended June 30, 2011, as well as net sales and...
-
Jul 28, 2011
Boston Scientific Corporation's (NYSE: BSX) Board of Directors has approved a new program authorizing the repurchase of up to $1.0 billion of its...
-
Jul 27, 2011Investment to support development of local manufacturing capabilities and training center
Boston Scientific Corporation's (NYSE: BSX) Board of Directors has approved a five-year, $150 million investment in China to expand its commercial...
-
Jul 21, 2011
Boston Scientific Corporation (NYSE: BSX) announces that Fitch Ratings has upgraded the Company's corporate credit rating to an investment grade...
-
Jul 14, 2011
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the second quarter ended June 30, 2011 on...
-
Jul 12, 2011European ASTI study to evaluate new nitinol stent to treat carotid artery disease
Boston Scientific Corporation (NYSE: BSX) has completed patient enrollment in the ASTI post-market clinical follow-up study designed to evaluate its...
-
Jul 5, 2011Boston Scientific's Galway Site in Ballybrit Commercializes Innovative Mustang™ PTA Balloon Catheter
Galway, Ireland (July 5, 2011) -- Boston Scientific’s Galway site in Ballybrit is manufacturing and distributing the Company’s recently launched Mustang™ Percutaneous Transluminal...
-
Jul 4, 2011Expanded Heredia plant to manufacture a broad line of medical devices
San José, (July 4, 2011) Boston Scientific Corporation (NYSE: BSX) today announced that it has completed the expansion of its manufacturing facility in Heredia, Costa Rica. This initiative will...
-
Jun 30, 2011
Boston Scientific Corporation (NYSE: BSX) welcomes the recent landmark report to Congress by the Institute of Medicine (IOM) of the National Academy of...
-
Jun 30, 2011Detachable coils for peripheral embolization offer precise placement and control in coiling procedures
Boston Scientific Corporation (NYSE: BSX) today announced the immediate U.S. and European launch of its Interlock™ – 35 Fibered IDC™ Occlusion...
-
Jun 27, 2011
Boston Scientific Corporation (NYSE: BSX) today welcomed approval by the U.S. House of Representatives of the America Invents Act of 2011. The...
-
Jun 20, 2011Low-profile, high-pressure balloon offers physicians exceptional performance in a single platform for peripheral angioplasty procedures
Boston Scientific Corporation (NYSE: BSX) today announced the global launch of its Mustang™ PTA Balloon Catheter, a highly deliverable 0.035 inch...
-
Jun 16, 2011
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2011 Wells Fargo Securities Healthcare Conference on June 22 in Boston....
-
Jun 7, 2011
Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed the decision of the U.S....
-
May 27, 2011Action affects products distributed in U.S. and its territories; Atlantis® SR Pro available immediately as a substitute
Boston Scientific Corporation (NYSE: BSX) today announced that it is voluntarily recalling all of its iCross™ Coronary Imaging Catheters used in...
-
May 25, 2011Boston Scientific becomes the first and only company to offer two distinct drug-eluting stents to treat small vessels
Boston Scientific Corporation (NYSE: BSX) today announced it has received approval from the U.S. Food and Drug Administration (FDA) to market its 2.25...
-
May 23, 2011New technology designed to improve lead anchoring for physicians to be introduced at INS World Congress
London, UK (May 23, 2011) – Boston Scientific Corporation (NYSE: BSX) today announced CE Mark approval of the Clik™ Anchor for its Precision Plus™ Spinal Cord Stimulator (SCS) System,...
-
May 23, 2011New technology designed to improve lead anchoring for physicians to be introduced at INS World Congress
London, UK (May 23, 2011) – Boston Scientific Corporation (NYSE: BSX) today announced CE Mark approval of the Clik™ Anchor for its Precision Plus™ Spinal Cord Stimulator (SCS) System,...
-
May 20, 201112-month clinical data demonstrate low adverse event rates for Boston Scientific's 2.25 mm PROMUS Element Platinum Chromium Stent
Boston Scientific Corporation (NYSE: BSX) today announced 12-month results from its PLATINUM Small Vessel study, demonstrating excellent...
-
May 18, 2011Results for Boston Scientific WATCHMAN device presented at EuroPCR
Boston Scientific Corporation (NYSE: BSX) today announced results from a clinical study evaluating the use of its WATCHMAN® Left Atrial...
-
May 16, 2011Five-year data from RISA Trial presented at ATS adds to clinical evidence showing long-term safety of Boston Scientific's Alair® Bronchial Thermoplasty System
Boston Scientific Corporation (NYSE: BSX) today announced long-term safety data from the Research in Severe Asthma (RISA) Trial, which...
-
May 11, 2011
Boston Scientific Corporation (NYSE: BSX) today announced that a jury in the District Court for the District of Delaware found that Cordis Corporation...
-
May 11, 2011Patients receive first device-based treatment for severe asthma
Natick, MA (May 11, 2011) -- Boston Scientific Corporation (NYSE: BSX) today announced the launch of its Alair® Bronchial Thermoplasty System in Canada. Doctors at Institut universitaire de...
-
May 10, 2011Elliott to remain on Board as non-executive director
Boston Scientific Corporation (NYSE: BSX) today announced that Ray Elliott will retire as President and Chief Executive Officer on December 31, 2011....
-
May 10, 2011Company sponsors additional efforts to promote education and awareness of severe asthma
Boston Scientific Corporation (NYSE: BSX) today announced its donation to the Asthma and Allergy Foundation of America (AAFA) to support education...
-
May 9, 2011Innovative Fine Needle Aspiration technology expands diagnostic capabilities in pancreas and gastrointestinal tract
Boston Scientific Corporation (NYSE: BSX) today announced the U.S. and international launch of its Expect™ Endoscopic Ultrasound Aspiration Needle,...
-
May 6, 2011World's smallest and thinnest high-energy CRT-Ds and ICDs offer new features to optimize patient management
Boston Scientific Corporation (NYSE: BSX) today announced the launch and first implants of its ENERGEN™ and PUNCTUA™ cardiac resynchronization...
-
May 5, 2011
Boston Scientific Corporation (NYSE: BSX) today announced results from an analysis of its ALTITUDE® Clinical Science program, which...
-
May 5, 2011
Boston Scientific Corporation (NYSE: BSX) today announced that it is offering a new warranty program in the U.S. that covers its cardiac...
-
May 4, 2011System used in 25,000 patient procedures at 600 facilities worldwide since 2007
Boston Scientific Corporation (NYSE: BSX) today announced several milestones in the adoption of its SpyGlass® Direct Visualization System since its...
-
May 3, 2011Radiofrequency ablation catheter designed to treat a variety of arrhythmias
Boston Scientific Corporation (NYSE: BSX) today announced CE Mark approval and first use in Europe of its Blazer™ Open-Irrigated Catheter, the...
-
May 2, 2011
Boston Scientific Corporation (NYSE: BSX) today announced its schedule of major events and sponsored research at the 32nd Annual Scientific Sessions of...
-
Apr 27, 2011
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Bank of America Merrill Lynch 2011 Health Care Conference on May 11 in...
-
Apr 26, 2011
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Deutsche Bank 36th Annual Healthcare Conference on May 2 in Boston. Ray...
-
Apr 25, 2011Innovative alloy designed to improve new coronary stent's acute performance
Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) approval and launch of the ION™ Paclitaxel-Eluting...
-
Apr 20, 2011
Boston Scientific Corporation (NYSE: BSX) today announced financial results for the first quarter ended March 31, 2011, as well as net sales and...
-
Apr 14, 2011
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the first quarter ended March 31, 2011 on...
-
Apr 5, 2011Innovative stent designed to treat peripheral vascular lesions for stenoses in arteries above the knee
Boston Scientific Corporation (NYSE: BSX) today announced the start of patient enrollment in the SuperNOVA clinical trial, an international,...
-
Apr 4, 2011Reduction of geographic miss and bail-out stenting observed with highly visible PROMUS Element Stent
Boston Scientific Corporation (NYSE: BSX) today announced 12-month results from the pivotal PLATINUM Workhorse trial comparing the...
-
Apr 3, 2011Lower event rates for new alloy and stent design versus older drug-eluting stent model
Boston Scientific Corporation (NYSE: BSX) today announced results from a pooled patient-level analysis of its PERSEUS and TAXUS ATLAS...
-
Mar 29, 2011Clinical presentations to include 12-month data on PROMUS Element™ Platinum Chromium Stent
Boston Scientific Corporation (NYSE: BSX) today announced its clinical trial news and events schedule at the 60th Annual Scientific Session of the...
-
Mar 24, 2011New technology designed to improve lead anchoring speed and consistency for physicians
Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) approval and U.S. launch of the Clik™ Anchor for...
-
Mar 22, 2011
Boston Scientific Corporation (NYSE: BSX) today announced that it will hold an analyst event on April 4, 2011 at the 60th Annual Scientific Session of...
-
Mar 8, 2011
Boston Scientific Corporation (NYSE: BSX) is scheduled to present at the Barclays Capital 2011 Global Healthcare Conference in Miami. Jeff Capello,...
-
Mar 7, 2011Third-generation bare-metal stent offers improved acute performance in treating patients with coronary artery disease
Boston Scientific Corporation (NYSE: BSX) today announced it has received CE Mark for its OMEGA™ Platinum Chromium Bare-Metal Coronary Stent System,...
-
Mar 3, 2011Company adds innovative technology for atrial fibrillation patients with high stroke risk
Boston Scientific Corporation (NYSE: BSX) today announced the completion of its acquisition of Atritech, Inc. of Plymouth, Minnesota. The completion...
-
Feb 17, 2011Company's third-generation drug-eluting stents now available in rapidly growing market
Boston Scientific Corporation (NYSE: BSX) today announced its launch of the PROMUS® Element™ Everolimus-Eluting Coronary Stent System and TAXUS®...
-
Feb 16, 2011
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2011 RBC Capital Markets' Healthcare Conference on March 2 in New York....
-
Feb 15, 2011New products expand treatment options for healthcare providers
Boston Scientific Corporation (NYSE: BSX) today announced the acquisition of two novel technologies to treat peripheral chronic total occlusions...
-
Feb 15, 2011Scholarship Fund Honors Company's Late Chief Medical and Scientific Officer
Boston Scientific Corporation (NYSE: BSX) today announced that it has established a $1.7 million endowment to fund the "Donald S. Baim, M.D., '75...
-
Feb 8, 2011
Boston Scientific Corporation (NYSE: BSX) today welcomed the publication of a sub-analysis of the MADIT-CRT trial data in the current issue of the...
-
Feb 3, 2011New system integrates market-leading Renegade HI-FLO Microcatheter with high-torque Fathom-16 Steerable Guidewire for peripheral embolization procedures
Boston Scientific Corporation (NYSE: BSX) today announced the availability of its Renegade® HI-FLO™ Fathom® Pre-Loaded System for selective...
-
Feb 1, 2011
Boston Scientific Corporation (NYSE: BSX) today announced financial results for the fourth quarter and full year ended December 31, 2010, as well as net...
-
Jan 28, 2011
Boston Scientific Corporation (NYSE: BSX) today announced that yesterday afternoon, the Civil Division of the U.S. Department of Justice (DOJ) filed a...
-
Jan 27, 2011Procedure performed as part of BLOCk-CTI clinical trial evaluating treatment of Type 1 atrial flutter
Boston Scientific Corporation (NYSE: BSX) today announced the first use of the Blazer® Open-Irrigated Catheter in the U.S. as part of the BLOCk-CTI...
-
Jan 26, 2011PLATINUM China trial to support Chinese regulatory approval of next-generation platinum chromium stent
Boston Scientific Corporation (NYSE: BSX) today announced the beginning of patient enrollment in the PLATINUM China clinical trial, which is designed...
-
Jan 24, 2011Fourth-generation stent features bioabsorbable polymer and everolimus drug coating
Boston Scientific Corporation (NYSE: BSX) today announced the completion of patient enrollment in the EVOLVE clinical trial, which is designed to...
-
Jan 19, 2011
Boston Scientific Corporation (NYSE: BSX) today announced that its subsidiary, Boston Scientific Japan K.K., has reached an agreement with Fukuda...
-
Jan 19, 2011
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the fourth quarter and year ended December...
-
Jan 19, 2011Innovative left atrial appendage closure device offers alternative for patients with atrial fibrillation and strengthens Company's position in emerging structural heart markets
Boston Scientific Corporation (NYSE: BSX) today announced the signing of a definitive merger agreement, under which the Company will acquire Atritech,...
-
Jan 10, 2011
Boston Scientific Corporation (NYSE: BSX) today announced that it has completed enrollment in the ORION clinical trial, which is designed to evaluate...
-
Jan 5, 2011Innovative technology designed to advance deep brain stimulation therapy
Boston Scientific Corporation (NYSE: BSX) today announced it has acquired Intelect Medical, Inc., a development-stage company located in...
-
Jan 4, 2011
Boston Scientific Corporation (NYSE: BSX) today issued the following statement from Kenneth Stein, M.D., Chief Medical Officer, Cardiac Rhythm...
-
Jan 4, 2011
Boston Scientific Corporation (NYSE: BSX) today announced the completion of its acquisition of Sadra Medical, Inc. of Los Gatos, California. The...
-
Jan 3, 2011Company prepays $600 million of debt
Boston Scientific Corporation (NYSE: BSX) today announced that it has completed the sale of its Neurovascular business to Stryker Corporation. The...
-
Dec 27, 2010
Boston Scientific Corporation (NYSE: BSX) is scheduled to present at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco. Ray...
-
Dec 20, 2010
Boston Scientific Corporation (NYSE: BSX) today announced that the Company's Board of Directors has elected Kristina M. Johnson, Ph.D., as a...